NCT06343532 - SXC-2023 Cocaine Interaction Study | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 11, 2024

Primary Completion Date

December 30, 2024

Study Completion Date

December 30, 2024

Conditions

Cocaine Use Disorder

Interventions

DRUG

SXC-2023

200 mg capsules

DRUG

SXC-2023 Placebo

200 mg capsules

Trial Locations (1)

Altasciences Clinical Kansas, Inc., Overland Park

All Listed Sponsors

collaborator

Promentis Pharmaceuticals, Inc.

INDUSTRY

collaborator

Altasciences Company Inc.

INDUSTRY

collaborator

Technical Resources International, Inc.

UNKNOWN

lead

National Institute on Drug Abuse (NIDA)

NIH